Stephen Born is the Co-Founder and Senior Director, Head of Scientific Affairs for Continuus Pharmaceuticals. After obtaining a PhD in organic chemistry from the University of California, San Diego,...
By Prof. Mo Jiang, Virginia Commonwealth University The pharmaceutical and chemical industries need scalable production of crystals with high quality in increasing atrributes, not only in terms of pure...
Mo Jiang is an Associate Professor in the Polytechnic School of Ira A. Fulton Schools of Engineering at Arizona State University. His research focuses on advancing the scalable precise...
By Dr. Kevin Girard, Pfizer Continuous processing of pharmaceuticals is a growing area of interest, with many companies engaged in the effort for both “flow chemistry” and continuous drug...
Kevin Girard received a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute in 1994. He later earned an M.S. and Ph.D. from the University of Pennsylvania in 1999. Dr....
By Dr. Michelle Liu, Abbvie Crystallization processes in pharmaceutical development are designed to reliably produce a solid form with a Pareto-optimal profile of multiple properties including stability, solubility,...
Michelle is a computational chemist in the Molecular Profiling and Drug Delivery at AbbVie, supporting drug development programs across the discovery–development continuum. Her work and research interests include prediction...
By Dr. Guanghui Zhu, Takeda Pharmaceuticals Particle engineering has emerged as a critical frontier in pharmaceutical process development, enabling control over drug formulation and delivery. By manipulating the size,...